posted on 2017-10-13, 00:00authored byYonghua Zhan, Sixiang Shi, Emily B. Ehlerding, Stephen A. Graves, Shreya Goel, Jonathan W. Engle, Jimin Liang, Jie Tian, Weibo Cai
Manganese oxide nanoparticles
(Mn3O4 NPs) have attracted a great deal of attention
in the field of biomedical imaging because of their ability to create
an enhanced imaging signal in MRI as novel potent T1 contrast agents. In this study, we present tumor vasculature-targeted
imaging in mice using Mn3O4 NPs through conjugation
to the anti-CD105 antibody TRC105 and radionuclide copper-64 (64Cu, t1/2: 12.7 h). The Mn3O4 conjugated NPs, 64Cu-NOTA-Mn3O4@PEG-TRC105, exhibited sufficient stability in
vitro and in vivo. Serial positron emission tomography (PET) and magnetic
resonance imaging (MRI) studies evaluated the pharmacokinetics and
demonstrated targeting of 64Cu-NOTA-Mn3O4@PEG-TRC105 to 4T1 murine breast tumors in vivo, compared
to 64Cu-NOTA-Mn3O4@PEG. The specificity
of 64Cu-NOTA-Mn3O4@PEG-TRC105 for
the vascular marker CD105 was confirmed through in vivo, in vitro, and ex vivo experiments. Since Mn3O4 conjugated NPs exhibited desirable properties for T1 enhanced imaging and low toxicity, the tumor-specific
Mn3O4 conjugated NPs reported in this study
may serve as promising multifunctional nanoplatforms for precise cancer
imaging and diagnosis.